The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Ivermectin for preventing and treating COVID-19
Open accessAbstract
BACKGROUND: Ivermectin, an antiparasitic agent used to treat parasitic infestations, inhibits the replication of viruses in vitro. The molecular hypothesis of ivermectin's antiviral mode of action suggests an inhibitory effect on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in the early stages of infection. Currently, evidence on efficacy and safety of ivermectin for prevention of SARS-CoV-2 infection and COVID-19 treatment is conflicting. OBJECTIVES: To assess the efficacy and safety of ivermectin compared to no treatment, standard of care, placebo, or any other proven intervention for people with COVID-19 receiving treatment as inpatients or outpatients, and for prevention of an infection with SARS-CoV-2 (postexposure prophylaxis). SEARCH METHODS: We searched the Cochrane COVID-19 Study Register, Web of Science (Emerging Citation Index and Science Citation Index), medRxiv, and Research Square, identifying completed and ongoing studies without language restrictions to 26 May 2021. SELECTION CRITERIA: We included randomized controlled trials (RCTs) comparing ivermectin to no treatment, standard of care, placebo, or another proven intervention for treatment of people with confirmed COVID-19 diagnosis, irrespective of disease severity, treated in inpatient or outpatient settings, and for prevention of SARS-CoV-2 infection. Co-interventions had to be the same in both study arms. We excluded studies comparing ivermectin to other pharmacological interventions with unproven efficacy. DATA COLLECTION AND ANALYSIS: We assessed RCTs for bias, using the Cochrane risk of bias 2 tool. The primary analysis excluded studies with high risk of bias. We used GRADE to rate the certainty of evidence for the following outcomes 1. to treat inpatients with moderate-to-severe COVID-19: mortality, clinical worsening or improvement, adverse events, quality of life, duration of hospitalization, and viral clearance; 2. to treat outpatients with mild COVID-19: mortality, clinical worsening or improvement, admission to hospital, adverse events, quality of life, and viral clearance; (3) to prevent SARS-CoV-2 infection: SARS-CoV-2 infection, development of COVID-19 symptoms, adverse events, mortality, admission to hospital, and quality of life. MAIN RESULTS: We found 14 studies with 1678 participants investigating ivermectin compared to no treatment, placebo, or standard of care. No study compared ivermectin to an intervention with proven efficacy. There were nine studies treating participants with moderate COVID-19 in inpatient settings and four treating mild COVID-19 cases in outpatient settings. One study investigated ivermectin for prevention of SARS-CoV-2 infection. Eight studies had an open-label design, six were double-blind and placebo-controlled. Of the 41 study results contributed by included studies, about one third were at overall high risk of bias. Ivermectin doses and treatment duration varied among included studies. We identified 31 ongoing and 18 studies awaiting classification until publication of results or clarification of inconsistencies. Ivermectin compared to placebo or standard of care for inpatient COVID-19 treatment We are uncertain whether ivermectin compared to placebo or standard of care reduces or increases mortality (risk ratio (RR) 0.60, 95% confidence interval (CI) 0.14 to 2.51; 2 studies, 185 participants; very low-certainty evidence) and clinical worsening up to day 28 assessed as need for invasive mechanical ventilation (IMV) (RR 0.55, 95% CI 0.11 to 2.59; 2 studies, 185 participants; very low-certainty evidence) or need for supplemental oxygen (0 participants required supplemental oxygen; 1 study, 45 participants; very low-certainty evidence), adverse events within 28 days (RR 1.21, 95% CI 0.50 to 2.97; 1 study, 152 participants; very low-certainty evidence), and viral clearance at day seven (RR 1.82, 95% CI 0.51 to 6.48; 2 studies, 159 participants; very low-certainty evidence). Ivermectin may have little or no effect compared to placebo or standard of care on clinical improvement up to 28 days (RR 1.03, 95% CI 0.78 to 1.35; 1 study; 73 participants; low-certainty evidence) and duration of hospitalization (mean difference (MD) -0.10 days, 95% CI -2.43 to 2.23; 1 study; 45 participants; low-certainty evidence). No study reported quality of life up to 28 days. Ivermectin compared to placebo or standard of care for outpatient COVID-19 treatment We are uncertain whether ivermectin compared to placebo or standard of care reduces or increases mortality up to 28 days (RR 0.33, 95% CI 0.01 to 8.05; 2 studies, 422 participants; very low-certainty evidence) and clinical worsening up to 14 days assessed as need for IMV (RR 2.97, 95% CI 0.12 to 72.47; 1 study, 398 participants; very low-certainty evidence) or non-IMV or high flow oxygen requirement (0 participants required non-IMV or high flow; 1 study, 398 participants; very low-certainty evidence). We are uncertain whether ivermectin
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
WITHDRAWN: Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic
Elgazzar, A., Eltaweel, A., Youssef, S. A., Hany, B., Hafez, M., & Moussa, H. (2020) · doi:10.21203/rs.3.rs-100956/v3 · Cited by 17
RetractedRoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-18 · Cited by 13,371
Dexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
An interactive web-based dashboard to track COVID-19 in real time
Dong, E., Du, H., & Gardner, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30120-1 · Cited by 10,048
GRADE guidelines: 3. Rating the quality of evidence
Balshem, H., Helfand, M., Schünemann, H. J., Oxman, A. D., Kunz, R., Brozek, J., Vist, G. E., Falck-Ytter, Y., Meerpohl, J., & Norris, S. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.015 · Cited by 8,285
Remdesivir for the Treatment of Covid-19 — Final Report
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007764 · Cited by 7,267
Factors associated with COVID-19-related death using OpenSAFELY
Williamson, E. J., Walker, A. J., Bhaskaran, K., Bacon, S., Bates, C., Morton, C. E., Curtis, H. J., Mehrkar, A., Evans, D., Inglesby, P., et al. (2020) · Nature · doi:10.1038/s41586-020-2521-4 · Cited by 6,674
Plea for routinely presenting prediction intervals in meta-analysis.
IntHout, J., Ioannidis, J. P. A., Rovers, M. M., & Goeman, J. J. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-010247 · Cited by 2,264
Kory, P., Meduri, G. U., Varon, J., Iglesias, J., & Marik, P. E. (2021) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001377 · Cited by 203
Research works printed but not linked: 89
- Ahmed, 2020, A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness, International Journal of Infectious Diseases, 103, 214, 10.1016/j.ijid.2020.11.191 · DOI · Paper page
- Chaccour C Casellas A Blanco-Di Matteo A Pineda I Fernandez-Montero A Ruiz-Castillo P The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with mild COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical trial researchsquare.com/article/rs-116547/v1 10.21203/rs.3.rs-116547/v1 · DOI
- Chaccour, 2021, The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical trial, EClinicalMedicine, 32, 100720, 10.1016/j.eclinm.2020.100720 · DOI · Paper page
- Chaccour, 2020, The SARS-CoV-2 ivermectin Navarra-ISGlobal Trial (SAINT) to evaluate the potential of ivermectin to reduce COVID-19 transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: a structured summary of a study protocol for a randomized control pilot trial, Trials, 21, 498, 10.1186/s13063-020-04421-z · DOI
- Chachar, 2020, Effectiveness of ivermectin in SARS-CoV-2/COVID-19 patients, International Journal of Sciences, 9, 31, 10.18483/ijSci.2378 · DOI
- Gonzalez BJ González Gámez M Enciso EA Maldonado RJ Palacios HP Dueñas Campos S Efficacy and safety of ivermectin and hydroxychloroquine in patients with severe COVID-19. A randomized controlled trial medrxiv.org/content/early/2021/02/23/2021.02.18.21252037 10.1101/2021.02.18.21252037 · DOI
- Kirti R Roy R Pattadar C Raj R Agarwal N Biswas B Ivermectin as a potential treatment for mild to moderate COVID-19 - a double blind randomized placebo-controlled trial medrxiv.org/content/10.1101/2021.01.05.21249310v1 10.1101/2021.01.05.21249310 · doi:10.1101/2021.01.05.21249310v1
- Kishoria, 2020, Ivermectin as adjuvant to hydroxychlorquine in patients resistant to standard treatment for SARS-CoV-2: results of an open-label randomized clinical study, Paripex - Indian Journal of Research, 9, 4801859, 10.36106/paripex/4801859 · DOI
- Krolewiecki A Lifschitz A Moragas M Travacio M Valentini R Alonso D Antiviral effect of high-dose ivermectin in adults with COVID-19: a pilot randomised, controlled, open label, multicentre trial ssrn.com/abstract=3714649 10.2139/ssrn.3714649 · DOI
- López-Medina, 2021, Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial, JAMA, 325, 1426, 10.1001/jama.2021.3071 · DOI · Paper page
- Mohan A Tiwari P Suri T Mittal S Patel A Jain A Ivermectin in mild and moderate COVID-19 (RIVET-COV): a randomized, placebo-controlled trial researchsquare.com/article/rs-191648/v1 10.21203/rs.3.rs-191648/v1 · DOI
- Okumuş, 2021, Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients, BMC Infectious Diseases, 21, 411, 10.1186/s12879-021-06104-9 · DOI
- Okumuş N Demirtürk N Çetinkaya RA Güner R Avcı IY Orhan S Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients researchsquare.com/article/rs-224203/v1 10.21203/rs.3.rs-224203/v1 · DOI
- Podder, 2020, Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomised controlled study, IMC Journal of Medical Science, 14, 11, 10.3329/imcjms.v14i2.52826 · DOI
- Pott-Junior, 2021, Use of ivermectin in the treatment of Covid-19: a pilot trial, Toxicology Reports, 8, 505, 10.1016/j.toxrep.2021.03.003 · DOI
- Shah Bukhari KH Asghar A Perveen N Hayat A Mangat SA Butt KR Efficacy of ivermectin in COVID-19 patients with mild to moderate disease medrxiv.org/content/early/2021/02/05/2021.02.02.21250840 10.1101/2021.02.02.21250840 · DOI
- Shoumann, 2021, Use of ivermectin as a potential chemoprophylaxis for COVID-19 in Egypt: a randomized clinical trial, Journal of Clinical and Diagnostic Research, 15, 27, 10.7860/JCDR/2021/46795.14529 · DOI
- Babalola OE Bode CO Ajayi AA Alakaloko FM Otrofanowei E Ivermectin shows clinical benefits in mild to moderate COVID19: a randomised controlled double-blind, dose-response study in Lagos Quarterly Journal of Medicine 10.1093/qjmed/hcab035 · DOI
- Babalola OE Bode CO Ajayi AA Alakaloko FM Otrofanowei E Ivermectin shows clinical benefits in mild to moderate COVID19: a randomised controlled double blind dose response study in Lagos medrxiv.org/content/10.1101/2021.01.05.21249131v1 10.1101/2021.01.05.21249131 · DOI
- Does ivermectin cure and/or prevent COVID-19? isrctn.com/ISRCTN40302986 10.1186/ISRCTN40302986 · DOI
- Behera P Patro BK Singh AK Chandanshive PD Ravi K Pradhan SK Role of ivermectin in the prevention of COVID-19 infection among healthcare workers in India: a matched case-control study 10.1101/2020.10.29.20222661 10.1101/2020.10.29.20222661 · DOI
- Goren A Wambier CG McCoy J Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly reduced symptoms compared to known outcomes in untreated patients medrxiv.org/content/10.1101/2020.10.31.20223883v1 10.1101/2020.10.31.20223883 · doi:10.1101/2020.10.31.20223883v1
- Cadegiani F Wambier CG Goren A McCoy J Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly reduced symptoms compared to known outcomes in untreated patients researchsquare.com/article/rs-100994/v1 10.21203/rs.3.rs-100994/v1 · DOI
- Cadegiani F Goren A McCoy J Wambier CG Hydroxychloroquine, nitazoxanide and ivermectin have similar effects in early COVID-19: a head-to-head comparison of the Pre-AndroCoV Trial researchsquare.com/article/rs-98106/v1 10.21203/rs.3.rs-98106/v1 · DOI
- Cadegiani F Goren A Wambier CG McCoy J An open-label prospective observational study of antiandrogen and non-antiandrogen early pharmacological approaches in females with mild-to-moderate COVID-19. The Pre-AndroCoV Female Trial medrxiv.org/content/10.1101/2020.10.05.20206870v1 10.1101/2020.10.05.20206870 · DOI
- Camprubi, 2020, Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients, PloS One, 15, e024218, 10.1371/journal.pone.0242184 · DOI
- Carvallo H Hirsch R Safety and efficacy of the combined use of ivermectin, dexamethasone, enoxaparin and aspirin against COVID 19 medrxiv.org/content/10.1101/2020.09.10.20191619v1 10.1101/2020.09.10.20191619 · doi:10.1101/2020.09.10.20191619v1
- Chahla RE Medina Ruiz L Mena T Brepe Y Terranova P Ortega ES A randomized trial - intensive treatment based in ivermectin and iota-carrageenan as pre-exposure prophylaxis for COVID-19 in healthcare agents medrxiv.org/content/10.1101/2021.03.26.21254398v1 10.1101/2021.03.26.21254398v1 · DOI
- Chahla RE Medina Ruiz L Mena T Brepe Y Terranova P Ortega ES Cluster randomised trials - ivermectin repurposing for COVID-19 treatment of outpatients with mild disease In primary health care centers researchsquare.com/article/rs-495945/v1 10.21203/rs.3.rs-495945/v1 · DOI
- Chahla RE Medina Ruiz L Mena T Brepe Y Terranova P Ortega ES Ivermectin reproposing for COVID-19 treatment outpatients in mild stage in primary health care centers medrxiv.org/content/10.1101/2021.03.29.21254554v1 10.1101/2021.03.29.21254554v1 · DOI
- Chowdhury, 2021, A comparative study on ivermectin-doxycycline and hydroxychloroquine-azithromycin therapy on COVID-19 patients, Eurasian Journal of Medicine and Oncology, 5, 63, 10.14744/ejmo.2021.16263 · DOI
- Chowdhury AT Islam J Dan G Shuixiang H A randomized trial of ivermectin-doxycycline and hydroxychloroquine-azithromycin therapy on COVID19 patients researchsquare.com/article/rs-38896/v1 10.21203/rs.3.rs-38896/v1 · DOI
- A clinical study to assess the efficacy and safety of Tinefcon in patients with moderate COVID-19 infection cochranelibrary.com/es/central/doi/10.1002/central/CN-02186249/full · doi:10.1002/central/cn-02186249/full
- Melo dos Santos N Asato MS Moreira A Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection Pathology Global Health 2021 115 4 235 42 10.1080/20477724.2021.1890887 · DOI
- Gorial FI Mashhadani S Sayaly HM Dakhil BD AlMashhadani MM Aljabory AM Effectiveness of ivermectin as add-on therapy in COVID-19 management (pilot trial) medrxiv.org/content/10.1101/2020.07.07.20145979v1 10.1101/2020.07.07.20145979 · DOI
- Hashim HA Maulood MF Rasheed AM Fatak DF Kabah KK Abdulamir AS Controlled randomized clinical trial on using Ivermectin with doxycycline for treating COVID-19 patients in Baghdad, Iraq medrxiv.org/content/10.1101/2020.10.26.20219345v1 10.1101/2020.10.26.20219345 · DOI · Paper page
- Lima-Morales, 2021, Effectiveness of a multidrug therapy consisting of ivermectin, azithromycin, montelukast, and acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico, International Journal of Infectious Diseases, 105, 598, 10.1016/j.ijid.2021.02.014 · DOI
- Mahmud, 2021, Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial, Journal of International Medical Research, 49, 1, 10.1177/03000605211013550 · DOI
- Morgenstern J Redondo JN De León A Canela JM Torres N Tavares J The use of compassionate Ivermectin in the management of symptomatic outpatients and hospitalized patients with clinical diagnosis of COVID-19 at the Medical Center Bournigal and the Medical Center Punta Cana, Rescue Group, Dominican Republic, from May 1 to August 10, 2020 medrxiv.org/content/10.1101/2020.10.29.20222505v1 10.1101/2020.10.29.20222505 · DOI
- Niaee MS Allami A Javadi A Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: a randomized multi-center clinical trial (preprint) researchsquare.com/article/rs-109670/v1 10.21203/rs.3.rs-109670/v1 · DOI
- Sherman MS Vogel F Sacks J ICON (Ivermectin in COvid Nineteen) study: use of ivermectin is associated with lower mortality in hospitalized patients with COVID19 medrxiv.org/content/10.1101/2020.06.06.20124461v2 10.1101/2020.06.06.20124461 · doi:10.1101/2020.06.06.20124461v2
- Sherman, 2021, Use of ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: the ivermectin in COVID nineteen study, Chest, 159, 85, 10.1016/j.chest.2020.10.009 · DOI · Paper page
- Seet, 2021, Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: an open-label randomized trial, International Journal of Infectious Diseases, 106, 314, 10.1016/j.ijid.2021.04.035 · DOI
- Effects of ivermectin in patients with COVID-19: a multicenter, double-blind, randomized, controlled clinical trial Clinical Therapeutics 10.1016/j.clinthera.2021.04.007 · DOI
- Sasank, 2020, Utility of ivermectin and doxycycline combination for the treatment of SARS-CoV-2, International Archives of Integrated Medicine, 7, 177
- Faisal, 2020, Potential use of azithromycin alone and in combination with ivermectin in fighting against the symptoms of COVID-19, Professional Medical Journal, 28, 737, 10.29309/TPMJ/2021.28.05.5867 · DOI
- Hosseini, 2021, The efficacy and safety of ivermectin in patients with mild and moderate COVID-19: a structured summary of a study protocol for a randomized controlled trial, Trials, 22, 4, 10.1186/s13063-020-04988-7 · DOI
- Samaha, 2021, Effects of a single dose of ivermectin on viral and clinical outcomes in asymptomatic SARS-CoV-2 infected subjects: a pilot clinical trial in Lebanon, Viruses, 13, 989, 10.3390/v13060989 · DOI
- Garcia, 2021, Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial, Trials, 22, 262, 10.1186/s13063-021-05236-2 · DOI
- Garica PJ Huratdo HM Urgae-Gil C Leon P Malaga G Chaccour C Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial researchsquare.com/article/rs-345747/v1 10.21203/rs.3.rs-345747/v1 · DOI
- Vallejos, 2020, Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial, Trials, 21, 965, 10.1186/s13063-020-04813-1 · DOI
- Ashour, 2019, Ivermectin: from theory to clinical application, International Journal of Antimicrobial Agents, 54, 134, 10.1016/j.ijantimicag.2019.05.003 · DOI
- British Ivermectin Recommendation Development panel The BIRD recommendation on the use of ivermectin for Covid-19 francesoir.fr/sites/francesoir/files/media-icons/bird-proceedings-02-03-2021-v151.pdf
- Bryant A Lawrie T Dowswell T Fordham E Mitchell S Hill S Ivermectin for prevention and treatment of COVID-19 infection American Journal of Therapeutics 10.1097/MJT.0000000000001402 · DOI · Paper page
- Caly, 2020, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Research, 178, e1047874, 10.1016/j.antiviral.2020.104787 · DOI · Paper page
- Campbell, 1983, Ivermectin: a potent new antiparasitic agent, Science, 221, 823, 10.1126/science.6308762 · DOI · Paper page
- Cochrane LSR Guidance for the production and publication of Cochrane living systematic reviews: Cochrane Reviews in living mode Available from community.cochrane.org/review-production/production-resources/living-systematic-reviews
- COVID-NMA working group The COVID-NMA initiative: a living mapping and living systematic review of Covid-19 trials covid-nma.com
- Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane Available from training.cochrane.org/handbook/archive/v6.1
- Deng, 2020, Clinical determinants for fatality of 44,672 patients with COVID-19, Critical Care, 24, e179, 10.1186/s13054-020-02902-w · DOI · Paper page
- Dourmishev, 2005, Ivermectin: pharmacology and application in dermatology, International Journal of Dermatology, 44, 981, 10.1111/j.1365-4632.2004.02253.x · DOI · Paper page
- Garegnani LI Madrid E Meza N Misleading clinical evidence and systematic reviews on ivermectin for COVID-19 BMJ Evidence Based Medicine 10.1136/bmjebm-2021-111678 33888547 · DOI
- Dornfeld, 2016, Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import, Scientific Reports, 6, e23138, 10.1038/srep23138 · DOI · Paper page
- González-Canga, 2008, The pharmacokinetics and interactions of ivermectin in humans, Journal of the American Association of Pharmaceutical Scientists, 10, 42, 10.1208/s12248-007-9000-9 · DOI · Paper page
- Herrmann, 2020, COVID-19 induced acute respiratory distress syndrome - a multicenter observational study, Frontiers in Medicine, 7, 599533, 10.3389/fmed.2020.599533 · DOI
- Higgins JP Eldridge S Li T Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020 Available from training.cochrane.org/handbook/archive/v6.1
- Higgins JP Savović J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020 Available from training.cochrane.org/handbook/archive/v6.1
- Higgins JP Li T Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020 Available from training.cochrane.org/handbook/archive/v6.1
- Hill A Abdulamir A Ahmed S Ashgar A Basri E Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection researchsquare.com/article/rs-148845/v1 10.21203/rs.3.rs-148845/v1 · DOI
- Huang, 2020, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, 395, 497, 10.1016/S0140-6736(20)30183-5 · DOI · Paper page
- Karagiannidis, 2020, Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study, Lancet Respiratory Medicine, 9, 853, 10.1016/S2213-2600(20)30316-7 · DOI · Paper page
- Kobayashi, 2020, Communicating the risk of death from novel coronavirus disease (COVID-19), Journal of Clinical Medicine, 9, 580, 10.3390/jcm9020580 · DOI · Paper page
- Lefebvre C Glanville J Briscoe S Littlewood A Marshall C Metzendorf MI Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020 Available from: training.cochrane.org/handbook/archive/v6.1
- Marshall, 2020, A minimal common outcome measure set for COVID-19 clinical research, Lancet Infectious Diseases, 20, e192, 10.1016/S1473-3099(20)30483-7 · DOI · Paper page
- Oran DP The proportion of SARS-CoV-2 infections that are asymptomatic: a systematic review Annals of Internal Medicine 2021 174 5 655 62 10.7326/M20-6976 · DOI · Paper page
- Panahi, 2015, The efficacy of topical and oral ivermectin in the treatment of human scabies, Annals of Parasitology, 61, 11
- Prescott, 2020, Recovery from severe COVID-19, JAMA, 324, 739, 10.1001/jama.2020.14103 · DOI
- University of Oxford Ivermectin to be investigated in adults aged 18+ as a possible treatment for COVID-19 in the PRINCIPLE trial principletrial.org/news/ivermectin-to-be-investigated-as-a-possible-treatment-for-covid-19-in-oxford2019s-principle-trial
- Review Manager Web (RevMan Web) Cochrane 2020
- Rodríguez-Mega, 2020, Latin America's embrace of an unproven COVID treatment is hindering drug trials, Nature, 586, 481, 10.1038/d41586-020-02958-2 · DOI
- Schünemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020 Available from training.cochrane.org/handbook/archive/v6.1
- Siemieniuk, 2020, A living WHO guideline on drugs for Covid-19, BMJ, 370, m379, 10.1136/bmj.m3379 · DOI · Paper page
- Singh, 2021, Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD013587.pub2 · DOI · Paper page
- Fraser, 2013, Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin, Antiviral Research, 99, 301, 10.1016/j.antiviral.2013.06.002 · DOI · Paper page
- Heaton, 2012, Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus, Biochemical Journal, 443, 851, 10.1042/BJ20120150 · DOI · Paper page
- Watson, 2020, Interpreting a Covid-19 test result, BMJ, 369, m1808, 10.1136/bmj.m1808 · DOI · Paper page
- Wulan, 2015, Nucleocytoplasmic transport of nucleocapsid proteins of enveloped RNA viruses, Frontiers in Microbiology, 6, e553, 10.3389/fmicb.2015.00553 · DOI
- Yang, 2020, The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer, Antiviral Research, 177, e104760, 10.1016/j.antiviral.2020.104760 · DOI · Paper page
- Popp, 2021, Ivermectin for preventing and treating COVID-19, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD015017 · DOI · Paper page
Cited by
Koc, H. C., Xiao, J., Liu, W., Li, Y., & Chen, G. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.75056 · Cited by 282
Randomized trial of metformin, ivermectin, and fluvoxamine for Covid-19.
Bramante, C. T., Huling, J. D., Tignanelli, C. J., Buse, J. B., Liebovitz, D. M., Nicklas, J. M., Cohen, K., Puskarich, M. A., Belani, H. K., Proper, J. L., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2201662 · Cited by 242
Ivermectin for preventing and treating COVID-19
Popp, M., Reis, S., Schießer, S., Hausinger, R. I., Stegemann, M., Metzendorf, M.-I., Kranke, P., Meybohm, P., Skoetz, N., & Weibel, S. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015017.pub3 · Cited by 169
Self-citationWeibel, S., Popp, M., Reis, S., Skoetz, N., Garner, P., & Sydenham, E. (2023) · Research Synthesis Methods · doi:10.1002/jrsm.1599 · Cited by 93
Self-citationFlawed ivermectin preprint highlights challenges of COVID drug studies.
Reardon, S. (2021) · Nature · doi:10.1038/d41586-021-02081-w · Cited by 83
Metadata
- Authors
- Popp, M., Stegemann, M., Metzendorf, M.-I., Gould, S., Kranke, P., Meybohm, P., Skoetz, N., & Weibel, S.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2021-07-28
- Volume
- 2021
- Issue
- 10
- Pages
- CD015017-CD015017
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W3153356117
- Cited by
- 167
- References
- 10
- FWCI
- 11.77
- Type
- journal article
- Language
- en
- Update notices
- new_version (2022-06-21)
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.